Press Releases

Dow Pharmaceutical Sciences, Inc., Dr. Daniel Bucks, Director of Drug Transport, to Present a New Bovine In Vitro Ocular Permeation Model at ARVO 2006 Annual Meeting

A Promising In Vitro Ophthalmic Product Testing Model Using Newborn Bovine Eyes

PETALUMA, CA – Dow Pharmaceutical Sciences, Inc.(DPSI), provides product development, clinical research and management services for the biotech and pharmaceutical industries. DPSI announced today that a new bovine in vitro ocular permeation model has been developed by a team led by Dr. Daniel Bucks, Director of Dow’s Drug Transport laboratory. Dr. Bucks will introduce this new drug testing model at a poster presentation at the 2006 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4th in Fort Lauderdale, Florida.

A Promising In Vitro Drug Testing Model Using Newborn Bovine Eyes

Currently, rabbit or adult bovine eyes are most commonly used for ocular drug penetration studies. Rabbit eyes are appropriate for corneal investigation but are not large enough for scleral testing. Adult bovine eyes are of adequate size for scleral testing but the corneas tend to be damaged.

Dr. Buck’s work demonstrates that newborn bovine eyes are of sufficient size for both scleral and corneal testing of drug permeation using the Bronaugh flow-through diffusion cell system. In addition, they are of a higher quality than adult bovine eyes. Lastly, drug permeation is significantly higher in newborn bovine cornea versus rabbit cornea. Thus the newborn bovine eye is a promising model to characterize ocular drug permeation, allowing measurement of both corneal and scleral drug permeation in the same species.

To preview the model in more detail, download a copy of the poster presentation at:
On DPSI’s Bovine Corneal/Scleral Permeation Model Click herepdf

Expanded Possibilities in Ophthalmic Product Development

The use of this model improves Dow’s ability to evaluate penetration of ophthalmic drug formulations. Using newborn bovine eyes from local sources as an integral part of our methodology, we can screen multiple APIs and we can evaluate and optimize multiple formulation prototypes to help select API’s and formulations for further development.

Dr Bucks’ Conference Availability

Dr Bucks will make a poster presentation on May 4 and will also be available at the Dow Pharmaceutical Sciences, Inc. booth #300 to discuss this new in vitro drug testing model and its exciting implications for ophthalmic product development.

Dr. Bucks manages the Drug Transport laboratory at Dow Pharmaceutical Sciences, Inc. a Petaluma, California company that specializes in the development of ophthalmic, dermatological, transdermal, vaginal and other topical drug products for clients. Formulations are evaluated and optimized using in vitro release and permeation studies conducted in Dow’s Drug Transport laboratory. DPSI also provides formulation and regulatory consulting services.

For more information:

On DPSI’s Bovine Corneal/Scleral Permeation Model Click herepdf

On Dow Pharmaceutical Sciences, Inc.: www.dowpharmsci.com

# # #

Contact: Steven R. Smith
Vice President, Marketing & Business Development
1330 Redwood Way, Petaluma, CA 94954
(707) 665-4672; ssmith@dowpharmsci.com

<< Back to Press Releases